Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10579229		
	Filing Date		2007-04-06		
	First Named Inventor	Vasso	Apostolopoulos		
	Art Unit		1632		
	Examiner Name				
	Attorney Docket Number	er	3489-103		

U.S.PATENTS									Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date	of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pate of cited Docu	Releva		ines where es or Relev		
	1										
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	GN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³			Kind Code ⁴	Publication Date	Applicant of cited		Pages,Colu vhere Rele Passages c Figures App	vant r Relevant	T5
	1	0175617	EP		B1	1991-10-30	Cytogen Corporation				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10579229				
Filing Date		2007-04-06				
First Named Inventor	Vasso	Vasso Apostolopoulos				
Art Unit		1632				
Examiner Name						
Attorney Docket Number		3489-103				

	1	Tang, Choon K., et al., "Mannan-mediated gene delivery for cancer immunotherapy," Immunology, 120(3): 325-335 (March 2007)								
	2	Apostolopoulos, Vasso, et al., "Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway," Eur. J. Immunol. 30(6): 1714-1723 (June 2000)								
	Sasaki, Shin, et al., "Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine," Eur. J. Immunol. 27(12): 3121-3129 (December 1997)									
	4	Apostolopoulos, Vasso, et al., "Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses," Proc. Natl. Acad. Sci. USA, 92: 10128-10132 (October 1, 1995)								
	5	Supplementary European Search Report for European Application 04797013 dated January 8, 2008								
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examiner	xaminer Signature		/Kimberly	Chong/			Date Considered		/Kimberly Cho	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.										